Anti-FCRLA immunotoxin E9 (scFv)-PE
This immunotoxin was achieved by conjugating/fusing the Anti-FCRLA scFv to Pseudomonas exotoxin. It was expressed in CHO and purified with affinity chromatography. The immunotoxin selectively binds to FCRLA expressed B-cell malignancies cells. Once bind, the toxin enters cells by receptor-mediated endocytosis. Then PE cleaved fragments the size of Mr 37000 and 27000, the large fragment and finally into the Golgi and elongation factor 2 (EM) combining it glycosylation inactivation, inhibition of protein synthesis, leading to apoptosis. It was designed for treating chronic lymphocytic leukemia; hairy cell leukemia and B-cell non-Hodgkin lymphoma.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AGTO-G026E |
| Pricing | Inquiry |
| Applications | This product is suitable for use in cytotoxicity assay, functional assay and immunotherapy. |
| Host | Mouse |
| Target | FCRLA |
| Species Reactivity | Human |